Cabozantinib most promising for refractory metastatic kidney cancer
In a European study of second-line treatments for metastatic kidney [...]
In a European study of second-line treatments for metastatic kidney [...]
Updated results from the phase 2 LITESPARK-003 trial with belzutifan [...]
This article gives some good advice about how to manage [...]
At the American Society of Clinical Oncology Annual Meeting (ASCO) last [...]
A recent study looked at the use of a combination [...]
The National Institute for Health and Care Excellence (NICE) has approved the [...]
Cabozantinib is a tyrosine kinase inhibitor that is used [...]
Treatments for people with metastatic kidney cancer have changed over [...]
Updated results and further follow up from the CaboNivo study [...]
The results of a study with a new anti-cancer medication [...]